Skip to main content
DIACEUTICS PLC logo

DIACEUTICS PLC — Investor Relations & Filings

Ticker · DXRX ISIN · GB00BJQTGV64 LEI · 213800VEWQBB39ZB8J81 IL Telecommunications, computer programming, consultancy, computing infrastructure, and other information service activities
Open in API
Filings indexed 278 across all filing types
Latest filing 2022-02-14 Director's Dealing
Country GB United Kingdom
Listing IL DXRX

About DIACEUTICS PLC

https://www.diaceutics.com/

Diaceutics PLC is a data analytics and end-to-end services provider focused on the development and commercialization of precision medicine diagnostics. The company supports pharmaceutical and biotech clients by providing solutions to improve the diagnostic testing ecosystem, aiming to ensure patients receive the correct personalized treatment. Its primary offering is DXRX, The Diagnostic Network®, a diagnostic commercialization platform for precision medicine. DXRX facilitates collaboration among stakeholders, including laboratories and pharmaceutical companies, in a secure marketplace and provides access to real-world diagnostic testing data. This integrated platform is designed to streamline the launch and adoption of new precision medicines.

Recent filings

Filing Released Lang Actions
PDMR Shareholding/Share Incentive Plan
Director's Dealing Classification · 99% confidence The document is an official notification filed via RNS (London Stock Exchange news service) dated February 14, 2022. The content explicitly details a 'PDMR Shareholding/Share Incentive Plan' transaction involving a director (Susanne Munksted) and the company's shares, referencing 'Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014'. This type of filing, reporting personal share transactions by company directors and executives (insider trades), directly corresponds to the definition of Director's Dealing (DIRS). Although it is distributed via RNS, the specific content dictates the DIRS classification over the general RNS fallback.
2022-02-14 English
Contract with leading life sciences company
Regulatory Filings Classification · 98% confidence The document is identified by the header 'RNS Number : 5095B' and concludes with boilerplate text referencing 'RNS, the news service of the London Stock Exchange'. The content announces a significant new contract win ('US$2.5m contract with leading life sciences company') and provides commentary from the CEO. This type of announcement, which is a material update but not a full financial report (like 10-K or IR) or a specific corporate action (like DIV or SHA), fits best under the general regulatory announcement category. Given the source (RNS) and the nature of the announcement (a significant business development update), the most appropriate classification is Regulatory Filings (RNS), as it is a general regulatory announcement.
2022-02-14 English
Director/PDMR Shareholding
Director's Dealing Classification · 99% confidence The document is identified by the RNS Number and the header 'RNS Number : 7636A'. The content explicitly details a 'PDMR Shareholding/Share Incentive Plan' transaction involving a Director (Stefan Macdonald) purchasing shares and receiving matched awards. This type of insider transaction report, specifically detailing dealings by a Person Discharging Managerial Responsibilities (PDMR), directly corresponds to the definition of Director's Dealing (DIRS). Although it is distributed via RNS, the specific content dictates the DIRS classification over the general RNS fallback.
2022-02-04 English
Directorate Change
Board/Management Information Classification · 99% confidence The document is an official announcement released via RNS (Regulatory News Service) on January 11, 2022. The title is "Directorate Change," and the content explicitly details the appointment of a new Chief Financial Officer (Nick Roberts) and the departure of the current CFO (Philip White). This directly corresponds to the definition of Board/Management Information (MANG). Although it is distributed via RNS, the specific content is about management change, making MANG the most precise classification.
2022-01-11 English
Trading Update and Notice of Results
Earnings Release Classification · 100% confidence The document is titled "Trading Update and Notice of 2021 Full Year Results" and provides unaudited trading highlights (Revenue, Adjusted EBITDA, Cash Balance) for the year ended 31 December 2021. This content structure—key unaudited figures released before the official audited report—is characteristic of an Earnings Release (ER). Crucially, the document explicitly states: "The Group's annual audited results will be announced on 22 March 2022." This confirms the current document is the preliminary announcement, not the full Annual Report (10-K) or the subsequent formal results announcement. It is a regulatory filing disseminated via RNS, but its specific content maps directly to the definition of an Earnings Release (ER). Since it is a specific financial performance summary, ER takes precedence over the general RNS category. FY 2021
2022-01-11 English
PDMR Shareholding/Share Incentive Plan
Director's Dealing Classification · 99% confidence The document is an RNS (Regulatory News Service) announcement from Diaceutics PLC, dated 31 December 2021. The content explicitly details 'PDMR Shareholding/Share Incentive Plan' transactions, specifically reporting share purchases and matched awards for Persons Discharging Managerial Responsibilities (PDMRs) under Article 19(1) of Regulation (EU) No. 596/2014. This type of filing, which reports personal share transactions by directors and executives, directly corresponds to the definition of Director's Dealing (DIRS). Although it is distributed via RNS, the specific content dictates the DIRS classification over the general RNS fallback.
2022-01-04 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.